Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock

Rocket Pharmaceuticals' general counsel, Martin Wilson, sold 631 shares of the company's common stock on August 18, 2026, for a total of $2,133. The shares were sold at $3.381 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). After this transaction, Wilson owned 673,853 shares of Rocket Pharmaceuticals common stock.

The company, with a market capitalization of $383 million, is currently trading at $3.48 per share. InvestingPro analysis suggests that RCKT is undervalued and listed among the platform's most undervalued stocks. The biotech company recently sold its Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, where shareholders approved the election of several directors.

TD Cowen maintains a Hold rating on the stock, citing the absence of safety events in early Danon disease patients treated with the company's gene therapy RP-A501.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.